# ‚öîÔ∏è TRIAL INTELLIGENCE REPORT: NCT06619236 ‚öîÔ∏è

**Trial Name**: Study to Assess the Efficacy of Rina-S Compared to Treatment...  
**Patient**: Ayesha Kiani (ID: ayesha_001)  
**Generated**: 2025-11-15T21:55:51.034053  
**Generated By**: Zo (Lead Commander)  
**Match Tier**: TOP_TIER  
**Composite Score**: 0.97/1.00  
**Eligibility Probability**: ~100%

**ClinicalTrials.gov**: https://clinicaltrials.gov/study/NCT06619236

---

## üî• WHY THIS MATTERS FOR AYESHA - CRITICAL ANALYSIS

**Status**: RECRUITING  
**Phase**: N/A  
**Sponsor**: Not specified

### ‚úÖ PIPELINE ASSESSMENT:

‚úÖ Status: RECRUITING
‚úÖ Ovarian cancer trial match
‚úÖ No stage restriction (assume eligible)
- ‚úÖ INTERVENTIONAL treatment trial
- ‚úÖ 7 NYC metro location(s)
- ‚ö†Ô∏è Eligibility: ~100% (pending biomarkers)

**Semantic Similarity**: 0.000 (vector search match)

---

## üß¨ ELIGIBILITY ASSESSMENT FOR AYESHA

| Criterion | Ayesha's Status | Match | Action Required |
|-----------|-----------------|-------|-----------------|
| Stage IV epithelial ovarian | Stage IVB High-Grade Serous Ovarian Carcinoma (HGSOC) | ‚úÖ PASS | None |
| BRCA wildtype | Germline negative | ‚úÖ PASS | None |
| HER2 Status | UNKNOWN | ‚ö†Ô∏è GATE | HER2 IHC (3-5 days) |
| HRD Status | UNKNOWN | ‚ö†Ô∏è PENDING | MyChoice CDx (7-10 days) |
| Treatment Line | first-line | ‚úÖ PASS | None |
| Tissue Available | True | ‚úÖ PASS | None |
| Performance Status | ECOG 1 | ‚úÖ PASS | None |
| Geographic Access | NYC Metro | ‚úÖ PASS | None |

**Probability Ayesha Is Eligible**: ~100%  
**Calculation**: No specific restrictions (100% eligible)

---

## üéØ WHY THIS TRIAL IS A GOOD FIT FOR AYESHA (LLM Analysis)

### **Clinical Analysis of NCT06619236 for Ayesha Kiani**

**TO:** Ayesha Kiani's Care Team
**FROM:** Clinical Oncology Expert
**DATE:** October 26, 2023
**RE:** Eligibility and Suitability Analysis for Trial NCT06619236

This analysis concludes that trial NCT06619236 is **not an appropriate option** for Ayesha Kiani at this time. The fundamental mismatch between her treatment-naive status and the trial's focus on platinum-resistant, recurrent disease makes her ineligible and renders the intervention clinically inappropriate as a first-line therapy.

---

#### **1. Drug Mechanism Fit**

The investigational agent, Rina-S (Rinatabart sesutecan), is a Folate Receptor alpha (FRŒ±)-targeting antibody-drug conjugate (ADC). This mechanism is highly relevant for HGSOC, as FRŒ± is overexpressed in a majority of these tumors. The ADC is designed to deliver a potent topoisomerase inhibitor payload directly to cancer cells, theoretically sparing normal tissue and overcoming certain resistance mechanisms.

However, the clinical context is paramount. ADCs like Rina-S are being studied for patients whose disease has progressed after standard platinum-based chemotherapy. For Ayesha, who is treatment-naive, the established first-line standard is a platinum doublet. Her extensive tumor burden and high CA-125 are indicative of a chemosensitive disease that is expected to respond well to initial platinum therapy. Introducing a later-line agent now would be a significant deviation from evidence-based care and would squander the most effective initial treatment strategy.

#### **2. Location Logistics**

While logistically feasible, this is secondary to clinical ineligibility. From her East Harlem ZIP code (10029), several trial sites are accessible:

*   **NYP-Weill Cornell Medical Center:** Excellent proximity (15-25 minutes via public transit/car).
*   **Perlmutter Cancer Center - 38th Street:** Accessible (30-45 minutes via subway).
*   **Herbert Irving Comprehensive Cancer Center (Columbia):** Accessible (30-40 minutes via subway).
*   **Perlmutter at NYU Langone - Long Island:** Not a practical option due to significant travel time.
*   **Mount Sinai (Miami Beach, FL):** Not a local site. Note: Mount Sinai's main campus in NYC is not listed as a site for this trial.

The availability of sites at major NYC academic centers is a strength of the trial, but it does not overcome the primary issue of ineligibility.

#### **3. Risk-Benefit for Ayesha**

The risk-benefit calculation is overwhelmingly negative for Ayesha in this context.

*   **Benefit:** There is no clinical benefit to forgoing a highly effective first-line standard of care for a second- or third-line experimental therapy. The response rates to agents used in the platinum-resistant setting are significantly lower than those expected from first-line carboplatin/paclitaxel.
*   **Risk:** The primary risk is the loss of the best opportunity for a deep and durable remission. Delaying or skipping standard front-line therapy would almost certainly lead to a worse clinical outcome. Furthermore, her compromised pulmonary status from large pleural effusions poses a specific risk. ADCs can carry a risk of interstitial lung disease (ILD)/pneumonitis. While often a low-frequency event, it would be a devastating complication in a patient with pre-existing pulmonary compromise. Her planned SOC, particularly with bevacizumab, is better suited to manage and resolve malignant pleural effusions.

#### **4. Comparison to Standard of Care (SOC)**

This trial is not a valid alternative or complement to Ayesha's planned SOC.

*   **Planned SOC (Carboplatin + Paclitaxel + Bevacizumab):** This is the gold standard for a patient with Stage IVB HGSOC and extensive tumor burden. It has a high objective response rate (>75%) and is the established backbone of front-line therapy. The addition of bevacizumab is particularly indicated for her, as it can help control malignant effusions and has been shown to improve progression-free survival in the front-line setting.
*   **Trial Intervention (Rina-S vs. Investigator's Choice Chemo):** This trial compares an experimental agent against single-agent chemotherapies (e.g., weekly paclitaxel, PLD) used for *platinum-resistant disease*. These comparator agents have response rates in the 15-25% range. Enrolling in this trial would mean receiving a therapy that is unequivocally inferior to her planned SOC.

#### **5. Critical Considerations for the Care Team**

1.  **Ineligibility is Definitive:** The core eligibility criteria requiring **1 to 4 prior lines of therapy** and documented **radiographic progression** immediately disqualify Ayesha. This is not a borderline case.

2.  **Prioritize Standard of Care:** The immediate clinical priority should be to initiate her planned SOC of Carboplatin/Paclitaxel/Bevacizumab as soon as her pleural effusions are medically managed (e.g., via thoracentesis) to stabilize her pulmonary status.

3.  **Complete Biomarker Testing:** It is critical to obtain Homologous Recombination Deficiency (HRD) status. If her tumor is HRD-positive (even if BRCA-negative), she would be a candidate for maintenance therapy with a PARP inhibitor (olaparib) in combination with bevacizumab following chemotherapy, which can significantly extend her progression-free survival.

4.  **Future Trial Consideration:** This trial, and others like it for platinum-resistant disease, may become relevant for Ayesha in the future *if* her disease recurs and demonstrates platinum resistance. For now, the focus must remain on optimizing her first-line treatment.

---


## üö® CRITICAL DECISION TREE FOR AYESHA

START: Ayesha completes carboplatin + paclitaxel + bevacizumab (L1)
  ‚îÇ
  ‚îú‚îÄ‚Üí Biomarker Testing (if required)
  ‚îÇ    ‚îÇ
  ‚îÇ    ‚îî‚îÄ‚Üí **ELIGIBLE FOR TRIAL!** (pending results)
  ‚îÇ         Probability: ~100%
  ‚îÇ
  ‚îî‚îÄ‚Üí END: Enroll in NCT06619236

---

## üí° STRATEGIC IMPLICATIONS

### Best-Case Scenario:
‚úÖ Ayesha enrolls in NCT06619236
‚úÖ Access to experimental therapy
‚úÖ Close monitoring, expert care
**Probability**: ~100%

### Most Likely Scenario:
Ayesha completes screening and enrolls successfully (pending biomarkers)

### Challenge Scenario:
Screen failure due to biomarker requirements or other eligibility criteria

---

## üìã FULL ELIGIBILITY TEXT

### Eligibility Criteria
Key 

* Participants must have histologically or cytologically confirmed high grade serous or endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
* Participants may be enrolled regardless of FRŒ± expression level.
* Participants must have received 1 to 4 prior lines of therapy. Participants must have progressed radiographically on or after their most recent line of therapy.
* Participants must have received prior treatment with the following therapies:

  * Platinum chemotherapy
  * Prior bevacizumab (or biosimilar) treatment is required, if labeled and available as standard of care per institutional guidelines, unless the participant has a documented contraindication or unless the participant is not eligible for treatment with bevacizumab (or biosimilar) due to precautions/intolerance
  * Participants with known or suspected deleterious germline or somatic breast cancer gene (BRCA) mutations and who achieved a complete or partial response to platinum-based chemotherapy must have been treated with a poly ADP-ribose polymerase (PARP) inhibitor as maintenance treatment unless the participant is not eligible for treatment with PARP inhibitor
  * Mirvetuximab soravtansine, if:

    * Mirvetuximab soravtansine is available in the enrollment region, and
    * The participant is eligible based on positive FRŒ± expression per Food and Drug Administration (FDA)-approved (or local equivalent) test, and
    * The participant does not have a documented medical exception, including chronic corneal disorders, history of corneal transplantation, or active ocular conditions requiring ongoing treatment/monitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and /or monocular vision.
* Participants must have platinum-resistant disease:

  * Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum therapy, and must have either had a response (CR or PR) or had non-measurable disease at the start of adjuvant platinum-based therapy, and then progressed between \> 91 days and ‚â§ 183 days after the date of the last dose of platinum.
  * Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 183 days after the date of the last dose of platinum.

Key * Prior therapy with an antibody-drug conjugate containing a topoisomerase 1 inhibitor.
* Have primary platinum-refractory disease, defined as ovarian cancer that did not respond (CR or PR) to or progressed ‚â§ 91 days after the last dose of a first-line platinum-containing regimen.
* History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (e.g., 5-year OS ‚â•90%), including, but not limited to, adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, ductal carcinoma in situ, or Stage I uterine cancer.
* Known active central nervous system metastases or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment, they have no new or enlarging brain metastases, and are off corticosteroids and anticonvulsants prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study drug. Participants with suspected brain metastases at screening should undergo a computed tomography (CT)/magnetic resonance imaging (MRI) of the brain prior to study entry.
* Hospitalization or clinical symptoms due to gastrointestinal obstruction within the past 91 days or radiographic evidence of gastrointestinal obstruction at the time of screening. Enrollment of participants who currently require parenteral nutrition must be discussed with the study medical monitor to determine eligibility.
* Ascites requiring frequent paracentesis (more often than approximately every 4 weeks) for symptomatic management. Enrollment of participants with an indwelling peritoneal catheter must be discussed with the medical monitor to determine eligibility.

NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

---

## üìä TRIAL DESCRIPTION

This phase 3 study will be conducted in different countries all over the world.

The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer.

Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose.

All participants will receive active drug; no one will be given placebo.

---

## üè• LOCATION DETAILS

### NYC Metro Locations (Priority for Ayesha)

1. **Yale School of Medicine** - New Haven, Connecticut
2. **Norwalk Hospital** - Norwalk, Connecticut
3. **Mount Sinai Comprehensive Cancer Center** - Miami Beach, Florida
4. **Perlmutter Cancer Center - 38th Street** - New York, New York
5. **Perlmutter Cancer Center at NYU Langone Hospital - Long Island** - New York, New York
6. **Herbert Irving Comprehensive Cancer Center** - New York, New York
7. **New York-Presbyterian - Weill Cornell Medical Center** - New York, New York

---

## ‚ö†Ô∏è CRITICAL GATES FOR AYESHA

‚úÖ No critical biomarker gates identified. Proceed with standard eligibility screening.

---

## ‚öîÔ∏è TACTICAL RECOMMENDATIONS

**Priority**: üî• **P0 - IMMEDIATE ACTION** (Eligibility: ~100%)

**Next Steps**:
1. **Order biomarker tests** (HER2 IHC, HRD if not done)
2. **Contact trial site** (within 48 hours)
3. **Pre-screen Ayesha** (get on coordinator's radar)
4. **Decision at Week 2**: Enroll if eligible
5. **Prepare medical records** (surgical report, pathology, CA-125 history)

**Expected Timeline**:
- Week 1: Complete L1 chemo (cycle 6)
- Week 2: Biomarker results available
- Week 3: Enroll in trial (if eligible) or proceed with SOC maintenance


---

## üéØ VALUE PROPOSITION

**WIN-WIN SCENARIO**:
- If eligible (100% chance) ‚Üí Access to experimental therapy
- If not eligible ‚Üí Gets proven SOC (PARP or bevacizumab maintenance)
- Either way, Ayesha receives appropriate care

**Risk-Benefit**: Low risk (pre-screening doesn't commit to enrollment), high reward (cutting-edge therapy)

---

## üìä PROVENANCE

**Generated By**: Zo (Lead Commander)  
**Pipeline Version**: v2.0 (Modular)  
**Data Source**: AstraDB vector search + Multi-stage filtering  
**Semantic Match Score**: 0.000  
**Composite Score**: 0.97 (Stage 1: 0.90, Stage 2: 0.95, Stage 3: 1.00, Stage 4: 1.00)  
**LLM Analysis**: Gemini gemini-2.5-pro  
**Quality**: ‚úÖ COMMANDER-GRADE INTELLIGENCE (Modular Pipeline v2.0)

---

**RESEARCH USE ONLY (RUO)** - This intelligence report is for research and strategic planning. All enrollment decisions must be reviewed by Ayesha's oncologist.

---

**‚öîÔ∏è FOR AYESHA!** ‚öîÔ∏è
